News for LivaNova PLC (LIVN)

Summary LivaNova PLC (LIVN), a prominent medical technology company, announced on [date of press release] that it has begun the process with the U.S. Centers fo

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it has initiated the process with the U.S. Centers for Medicare and M

LivaNova (LIVN) has begun efforts to expand Medicare coverage for its VNS Therapy, specifically targeting individuals with unipolar treatment-resistant depressi

LivaNova PLC (LIVN) initiates process for Medicare reconsideration of VNS Therapy coverage for treatment-resistant depression. The RECOVER study shows s

Summary LivaNova PLC (LIVN), a leading medical technology company, announced that its Chief Executive Officer, Vladimir Makatsaria, will participate in a firesi

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a f

LivaNova PLC (NASDAQ:LIVN) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ETCompany ParticipantsBriana Gotlin – Vice President, Investor...

The following slide deck was published by LivaNova PLC in conjunction with their 2025 Q1 earnings call.

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2025 and updated full-ye

LivaNova (LIVN) reported impressive first-quarter revenue of $316.9 million, surpassing the market consensus of $302.37 million. This growth was primarily fuele

Revenue: Achieved $316.9 million, surpassing the estimated $302.34 million, marking a 7.4% increase year-over-year.Adjusted EPS: Reported at $0.88, significant

LivaNova (LIVN) has released encouraging 12-month results from its OSPREY trial, which assesses the aura6000 System's effectiveness for treating moderate to sev

LivaNova's OSPREY clinical trial shows a 65% responder rate for moderate to severe obstructive sleep apnea at 12 months. The trial demonstrates a 68% re

LivaNova PLC reports strong Q1 results with Non-GAAP EPS of $0.88, beating estimates by $0.12, and revenue of $316.9M, up 7.5% Y/Y.

Shares of LivaNova PLC (LIVN) fell 2.35% in mid-day trading on Mar 22. The stock reached an intraday low of $39.16, before recovering slightly to $39.51, do

Shares of LivaNova PLC (LIVN) surged 0.40% in mid-day trading on Mar 19. The stock reached an intraday high of $40.90, before settling at $40.57, up from it

We recently compiled a list of the 7 Best Medical Technology Stocks To Buy According To Analysts. In this article, we are going to take a look at where LivaNova PLC (NASDAQ:LIVN) stands against the other...

Robust growth in Cardiopulmonary and Neuromodulation segments, with net revenue increases of 13.1% and 6.6% respectively.Effective management of supply chain d

Organic Revenue Growth (2024): 11% for the full year.Revenue Growth (Q4 2024): 5% overall, 7% organic growth compared to Q4 2023.Adjusted Operating Income Grow